CHCT:NYE-Community Healthcare Trust Incorporated (USD)

COMMON STOCK | REIT—Healthcare Facilities | NYE

Last Closing Price

USD 45.84

Change

+0.26 (+0.57)%

Market Cap

USD 0.92B

Volume

0.06M

Average Target Price

USD 47.67 (+3.98%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Community Healthcare Trust Incorporated is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in non-urban markets throughout the United States. The Company had investments of approximately $566.3 million in 111 real estate properties as of September 30, 2019, located in 32 states, totaling approximately 2.5 million square feet.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-01-24 )

Largest Industry Peers for REIT—Healthcare Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
WELL Welltower Inc

-0.29 (-0.33%)

USD35.40B 31.18 21.92
VTR Ventas, Inc

+0.35 (+0.60%)

USD21.93B 44.43 18.66
MPW Medical Properties Trust, Inc

N/A

USD11.59B 27.93 25.62
OHI Omega Healthcare Investors, In..

+0.06 (+0.14%)

USD9.46B 26.56 18.29
HTA Healthcare Trust of America, I..

+0.24 (+0.75%)

USD6.65B 180.34 22.89
HR Healthcare Realty Trust Incorp..

+0.04 (+0.11%)

USD4.76B 171.11 25.06
NHI National Health Investors, Inc

+0.08 (+0.09%)

USD3.78B 23.94 17.97
DOC Physicians Realty Trust

+0.12 (+0.62%)

USD3.69B 84.72 20.92
GEO The GEO Group, Inc

-0.15 (-0.92%)

USD1.96B 11.91 11.05
LTC LTC Properties, Inc

-0.19 (-0.40%)

USD1.87B 19.07 18.62

ETFs Containing CHCT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (REIT—Healthcare Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.95% 100% A+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.95% 100% A+ 91% A-
Trailing 12 Months  
Capital Gain 44.15% 92% A- 91% A-
Dividend Return 5.17% 58% F 80% B-
Total Return 49.32% 92% A- 92% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.49% 100% A+ 92% A-
Dividend Return 6.19% 75% C 87% B+
Total Return 28.68% 100% A+ 95% A
Risk Return Profile  
Volatility (Standard Deviation) 16.44% 75% C 47% F
Risk Adjusted Return 174.43% 100% A+ 98% A+
Market Capitalization 0.92B 15% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(REIT—Healthcare Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 279.63 8% F 2% F
Price/Book Ratio 2.92 23% F 31% F
Price / Cash Flow Ratio 37.63 15% F 7% F
EV/EBITDA 28.92 23% F 12% F
Management Effectiveness  
Return on Equity 1.47% 15% F 27% F
Return on Invested Capital 3.37% 31% F 30% F
Return on Assets 2.09% 31% F 41% F
Debt to Equity Ratio 38.57% 100% A+ 71% C-
Technical Ratios  
Short Ratio 2.20 92% A- 54% F
Short Percent 2.35% 100% A+ 75% C
Beta 0.66 23% F 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector